
    
      This is a double-blind, parallel-group, placebo-controlled, multiple-dose, single-site study
      in healthy male and female volunteers. Oral azimilide 125 mg or placebo will be administered
      every 12 hours for 3 days, followed by 125 mg every 24 hours for 3 days. The study will
      include a total of 21 healthy subjects (14 active and 7 placebo), all of whom will be
      confined at the study center for 9 nights.
    
  